Hear directly from the physician-researchers who are diabetes news makers helping to reshape the understanding of Type 2 diabetes. Leading endocrinologists will explain the latest research in the emerging field of incretin hormones and their potential role in diabetes treatment. New therapies currently under investigation that move beyond insulin-mediated treatments to a multi dimensional approach that may alter the usual progression of Type 2 disease will be discussed. The role of glucagon in diabetes, pancreatic islet function (beta cell and alpha-cell), and insulin/glucagon balance also will be discussed.
WHEN: 12 p.m. EST, Wednesday, May 18 -- Lunch will be served
Remote audio/Web access is available.
WHERE: American Association of Clinical Endocrinologists 14th Annual Meeting
and Clinical Congress
Marriott Wardman Park Hotel (same hotel as Annual Meeting), Washington, D.C.
Balcony A
WHO: Alan Garber, M.D., Ph.D. (moderator, panel member)
Professor of Medicine, Baylor College of Medicine
James Gavin, M.D., Ph.D. (speaker, panel member)
Clinical Professor of Medicine, Emory University School of Medicine
David D'Alessio, M.D. (speaker, panel member)
Associate Professor of Medicine, University of Cincinnati
WHY: Over 20 million Americans suffer from diabetes; approximately one-third of individuals with diabetes are undiagnosed. An additional 41 million have pre diabetes a condition that often leads to diabetes if left untreated. These numbers are only increasing, creating a modern epidemic. By participating in this lunchtime teach-in, you will collect valuable information and insights about cutting edge science and treatment approaches on the horizon for Type 2 diab
'"/>
Contact: Justin Wills
diabetesteachin@fleishman.com
816-512-2387
Fleishman-Hillard, Inc.
11-May-2005